Table 1 All of the involved markers in CRC susceptibility among the Iranian patients
From: Genetic and molecular origins of colorectal Cancer among the Iranians: an update
| STUDY (ET AL) | Year | Gene | population | Results |
|---|---|---|---|---|
| Nomani [14] | 2005 | GST |
39 controls 60 patients | Over activity in tumors |
| Ebrahimkhani [15] | 2012 | GSTT1 |
100 controls 100 patients | Polymorphism was correlated with CRC risk |
| Jamhiri [16] | 2017 | SOD1 |
239 controls 204 patients | Polymorphism was correlated with CRC risk |
| Mokarram [19] | 2015 | UBE2Q1 |
50 controls 60 patients | Hyper Methylation |
| Mokarram [19] | 2015 | UBE2Q2 |
50 controls 60 patients | Un methylation and stage of tumor |
| Amirghofran [22] | 2009 | TGFB1 |
138 controls 134 patients | Polymorphism was correlated with CRC risk |
| Damavand [24] | 2015 | SMAD7 |
253 controls 234 patients | Polymorphism was correlated with CRC risk |
| Naghibalhossaini [29] | 2012 | AXIN2 |
170 controls 112 patients | Methylation with stage and sex |
| Samaei [30] | 2014 | APC, AXIN2, DKK3, SFRP2, 4, 5, WIF1, and WNT5a | 125 N/Ta | Methylation |
| Naini [31] | 2016 | SFRP2 |
25 controls 48 polyps | Hyper Methylation as precancerous marker |
| Nemati [34] | 2015 | IL-17A |
203 controls 202 patients | Polymorphism was correlated with CRC risk |
| Azimzadeh [38] | 2011 | IL-16 |
405 controls 260 patients | Polymorphism was correlated with CRC risk |
| Al-Samadi [39] | 2016 | IL-17F | 10 tumors | Under expression in tumors |
| Ahangari [42] | 2014 | NOD2 |
88 controls 88 patients | Polymorphism was correlated with CRC risk |
| Azimzadeh [43] | 2013 | CD86 |
150 controls 150 patients | Polymorphism was correlated with CRC risk |
| Abtahi [44] | 2017 | IL-10 |
30 controls 58 patients | Lower levels in CRC patients |
| Habibollahi [49] | 2010 | COX2, iNOS | 17 patients | Correlation with lymph node metastasis |
| Hadinia [52] | 2007 | CTLA4 |
190 controls 109 patients | Polymorphism was correlated with CRC risk |
| Shafaei [53] | 2013 | CD166 | 121 N/T | Correlation with tumor location |
| Mahmoudi [56] | 2016 | ADIPOQ, ADIPOR1 |
339 controls 261 patients | Polymorphism was correlated with CRC risk |
| Motlagh [58] | 2007 | EGFR | 34 N/T | Marker of preoperative therapy response |
| Tavangar [59] | 2005 | HER2 | 55 N/T | Correlation with tumor size, stage, differentiation |
| Orang [61] | 2014 | STYK1/NOK | 40 N/T | Correlation with tumor size, stage |
| Tavakoli Koudehi [63] | 2018 | AKAP4 | 62 N/T | Correlation with liver metastasis in CRC patients |
| Hamzehzadeh [65] | 2018 | KRAS | 87 patients | Mutation |
| Koochak [68] | 2016 | KRAS | 1000 patients | Correlation with age, tumor type |
| Omidifar [69] | 2015 | KRAS | 100 patients | Mutation |
| Ghavam-Nasiri [71] | 2007 | P53 | 100 patients | Correlation with stage |
| Asadi [74] | 2018 | CASPASE3 | 50 N/T | Under expression |
| Golmohammadi [75] | 2013 | P53 | 61 patients | Correlation with distal tumors, sex, survival |
| Moossavi [77] | 2018 | VDR |
100 controls 100 patients | Polymorphism was correlated with CRC risk |
| Mahmoudi [78] | 2010 | VDR |
180 controls 160 patients | Polymorphism was correlated with CRC risk |
| Mahmoudi [82] | 2016 | IRS1 |
438 controls 312 patients | Polymorphism was correlated with CRC risk |
| Karimi Mazraehshah [86] | 2018 | miR-200c, BMI1 |
38 controls 38 patients | Under an over expression, respectively |
| Orang [90] | 2014 | miR-205 | 36 N/T | Correlation with lymph node metastasis, stage |
| Basati [91] | 2014 | miR-21 |
40 controls 40 patients | Correlation with stage |
| Bastaminejad [92] | 2017 | miR-21 |
40 controls 40 patients | Correlation with stage |
| Basati [95] | 2016 | miR-194 |
55 controls 55 patients | Correlation with stage |
| Eslamizadeh [105] | 2018 | miR-135b, 20a, 31, 21 |
32 controls 74 patients | Increased levels in CRC patients |
| Montazer Haghighi [107] | 2009 | MMR |
248 controls 592 patients | Novel mutations in PMS2 and MLH1 |
| Shahmoradi [108] | 2012 | hMLH1 | 20 patients | Novel mutations |
| Moghbeli [110] | 2011 | MMR | 67 N/T | MSI was correlated with location, stage, lymph node metastasis |
| Faghani [111] | 2012 | MMR | 96 N/T | MSI was correlated with location |
| Nazemalhosseini Mojarad [112] | 2016 | MMR | 158 N/T | MSI was correlated with differentiation, stage, sex |
| Brim [113] | 2008 | MMR | 53 patients | MSI was correlated with differentiation |
| Khatami [114] | 2009 | MGMT |
213 controls 208 patients | Polymorphism was correlated with CRC risk |
| Farzanehfar [115] | 2013 | MGMT | 40 N/T | Methylation |
| Nemati [117] | 2018 | HDAC3 | 48 N/T | Correlation with stage, differentiation |
| Ayoubi [121] | 2017 | H3.3B | 36 N/T | Correlation with stage, lymph node |
| Mohammed [125] | 2015 | tRNALeu(CUN) |
100 controls 30 patients | Mutation |
| Haghighi [128] | 2008 | MTHFR |
239 controls 227 patients | Polymorphism was correlated with CRC risk |
| Naghibalhossaini [131] | 2010 | MTHFR |
231 controls 175 patients | Polymorphism was correlated with CRC risk |
| Samanian [136] | 2011 | MDR1 |
60 controls 60 patients | Correlation with grade |
| Khedri [137] | 2011 | MDR1 |
137 controls 118 patients | Correlation with stage |
| Ardalan Khales [138] | 2015 | SALL4 | 111 N/T | Correlation with grade, depth of invasion |
| Raeisossadati [143] | 2014 | DPPA2, HIWI | 46 N/T | Correlation with stage, lymph node metastasis |
| Mirzaei [146] | 2015 | LGR5, DCLK1 |
58 controls 58 patients | Correlation with stage |
| Niknami [149] | 2017 | FIBRONECTIN | 45 patients | Correlation with grade |
| Hosseini [150] | 2018 | NEBL | 67 N/T | Correlation with lymph node metastasis |
| Behrouz Sharif [153] | 2016 | SEPT9 | 45 N/T | Methylation |
| Raeisossadati [154] | 2011 | CEA, TEM8 |
40 controls 40 patients | Over expression in CRC patients |